Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Michigan
Clinical trial register · United States · industry-sponsored

Clinical Trials in Michigan, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca53 Janssen Research & Development, LLC41 Eli Lilly and Company40 AbbVie35 Merck Sharp & Dohme LLC34
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Michigan

1484 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Safety Study of XT-150 in Participants With ALS
NCT06704347Amyotrophic Lateral Sclerosis (ALS)
Xalud Therapeutics, Inc.
Phase 1
8
Arizona, Maryland, Massachusetts, Michigan
2027-03
Not yet open
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562Systemic Sclerosis
DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Arizona, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2027-02-03
Not yet open
Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression
NCT07809906CD123+ Acute Myeloid Leukemia
Orum Therapeutics USA, Inc.
Phase 1
42
Michigan, Texas
2026-12
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
DrugNerandomilast
Boehringer Ingelheim
Phase 3
270
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Michigan
2026-11-09
Recruiting
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
NCT07310420Advanced Breast Cancer, Early Breast Cancer
DrugZoladex
TerSera Therapeutics LLC
Phase 1
176
Arkansas, District of Columbia, Florida, Georgia, Illinois, Louisiana, Michigan, Montana
2026-10-30
Recruiting
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
NCT07811869Chronic Pruritus of Unknown Origin
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Florida, Massachusetts, Michigan, Ohio
2026-10-06
Not yet open
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
NCT07845500Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
DrugsBerobenatide·Tirzepatide·Semaglutide
Pfizer
Phase 3
660
Alabama, Florida, Kentucky, Michigan, Missouri, Montana, North Carolina, Ohio
2026-10-01
Recruiting
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
NCT07673744Myasthenia Gravis
DrugUblituximab
TG Therapeutics, Inc.
Phase 2
120
Colorado, Florida, Michigan, North Carolina, South Carolina
2026-10-01
Recruiting
Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome
NCT05847179Werner Syndrome
PRG Science & Technology Co., Ltd.
Phase 2
5
Michigan
2026-10
Not yet open
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT07843459Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Eli Lilly and Company
Phase 1
111
California, Florida, Georgia, Michigan
2026-10
Recruiting
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
NCT07219238Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma
GE Healthcare
Phase 2/3
175
Michigan
2026-10
Recruiting
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
NCT07473700Hypertension, Pulmonary, Lung Diseases, Interstitial
Tectonic Operating Company, Inc.
Phase 2
25
Arizona, California, Idaho, Michigan
2026-10
Recruiting
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
NCT07831824Prostate Cancer
Lantheus Medical Imaging
Phase 2/3
408
Michigan
2026-09-30
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170Non-small Cell Lung Cancer
DrugsDivarasib·Opdivo·Nivolumab·Keytruda
Hoffmann-La Roche
Phase 3
400
California, Georgia, Michigan, Nevada, New Mexico
2026-09-30
Not yet open
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Alaska, Maryland, Michigan, New York, Ohio, Pennsylvania, West Virginia
2026-09-29
Recruiting
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
NCT07700979Gastric / Gastroesophageal Junction Adenocarcinoma
DrugsFolfox·Cadonilimab·Nivolumab
Akeso
Phase 3
900
Arizona, California, Colorado, Connecticut, Massachusetts, Michigan, New York, Oregon
2026-09-24
Not yet open
A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
NCT07723963Juvenile Myoclonic Epilepsy
DrugCannabidiol
Jazz Pharmaceuticals
Phase 2/3
260
Arizona, Connecticut, Florida, Georgia, Hawaii, Idaho, Louisiana, Michigan
2026-09-18
Recruiting
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
NCT07540988Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
466
Alabama, California, Connecticut, Florida, Indiana, Kansas, Michigan, Minnesota
2026-09-17
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193Colorectal Adenocarcinoma
DrugsVVD-133214·Pembrolizumab
Vividion Therapeutics, Inc.
Phase 2
140
Arizona, Michigan, West Virginia
2026-09-11
Recruiting
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
NCT07775924Cutaneous Lichen Planus
DrugGIA632
Novartis Pharmaceuticals
Phase 2
259
Alabama, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2026-09-10
Recruiting
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
NCT07465718Wilson's Disease
Orphalan
Phase 3
38
Colorado, Connecticut, Michigan
2026-09-03
Not yet open
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
NCT07781852Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
Lumina Pharmaceuticals Inc
Phase EARLY_PHASE1
40
Massachusetts, Michigan, New York
2026-09-01
Not yet open
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
NCT07808697SARS-CoV-2
DrugsMRNA-1283·Efluelda (TIV-HD) and Spikevax
ModernaTX, Inc.
Phase 2
300
California, Florida, Illinois, Michigan, Ohio, Texas, Utah, Virginia
2026-09-01
Not yet open
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab
NCT07832136Thyroid Eye Disease
Viridian Therapeutics, Inc.
Phase 4
30
California, Florida, Massachusetts, Michigan, Missouri, New Jersey, Texas
2026-09
Recruiting
REC-7735 in Participants With Solid Tumors
NCT07819136Solid Tumors
Recursion Pharmaceuticals Inc.
Phase 1/2
90
Michigan, Texas, Virginia
2026-09
Recruiting
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
NCT07804615PARKINSON DISEASE (Disorder)
DrugVIM0423
Vima Therapeutics
Phase 2
80
Arizona, California, Connecticut, Florida, Georgia, Kansas, Maryland, Michigan
2026-09
Not yet open
New Functional Ingredient for Oral Care
NCT07771907Oral Health Related Quality of Life (OHRQoL)
Access Business Group
Not applicable
100
Michigan
2026-09
Recruiting
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
NCT07804186Uveal Melanoma
DrugsDarovasertib·Crizotinib
IDEAYA Biosciences
Phase 3
450
Arizona, California, Massachusetts, Michigan, New York, North Carolina, Ohio, Pennsylvania
2026-09
Not yet open
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
NCT07787182Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
DrugLY4405094
Eli Lilly and Company
Phase 1
68
California, Florida, Georgia, Michigan
2026-09
Recruiting
JUR-003 in Adult Patients With Metastatic Prostate Cancer
NCT07824349Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Metastatic Hormone Sensitive Prostate Cancer
Juri Biosciences, Inc.
Phase 1
210
Michigan, New York, Tennessee
2026-09
Recruiting
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
NCT07722741HCC
DrugsGNOS-PV02·INO-9012
Geneos Therapeutics
Phase 2
90
Georgia, Louisiana, Maryland, Michigan, New York, Texas, Washington
2026-09
Not yet open
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
NCT07787169Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
DrugLY4405094
Eli Lilly and Company
Phase 1
179
California, Florida, Georgia, Michigan
2026-09
Recruiting
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
1,072
Arizona, California, Florida, Illinois, Michigan, Minnesota, Nebraska, New York
2026-08-31
Not yet open
An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes
NCT07795606Estrogen Therapy
Bayer
Observational
456,000
Michigan, Minnesota
2026-08-31
Recruiting
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
NCT07778316Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
400
Florida, Michigan, Nebraska
2026-08-28
Recruiting
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
NCT07768371IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
576
Alabama, Arizona, Arkansas, California, Georgia, Illinois, Maryland, Michigan
2026-08-27
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
NCT07729462Preventive Treatment of Migraine
DrugRimegepant
Pfizer
Phase 3
400
Arizona, California, Florida, Indiana, Massachusetts, Michigan, Missouri, Nebraska
2026-08-26
Not yet open
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)
DrugsASCT·AZD0120·Melphalan·Lenalidomide
AstraZeneca
Phase 3
750
Florida, Georgia, Illinois, Michigan, Minnesota, Ohio, Texas, Washington
2026-08-25
Recruiting
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
NCT07795814Heart Failure With Preserved Ejection Fraction
Edgewise Therapeutics, Inc.
Phase 2
90
Alabama, California, Illinois, Indiana, Kentucky, Louisiana, Maryland, Michigan
2026-08-25
Recruiting
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
NCT07541079Early Breast Cancer
DrugGiredestrant
Genentech, Inc.
Phase 3
300
California, Michigan
2026-08-25
Recruiting
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
NCT07214376Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
Pulnovo Medical, Inc.
Not applicable
750
Arizona, Louisiana, Massachusetts, Michigan, New York, Ohio, Oklahoma, Pennsylvania
2026-08-21
Recruiting
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
NCT07783542Hidradenitis Suppurativa (HS)
DrugORKA-002
Oruka Therapeutics, Inc.
Phase 2
200
Alabama, California, Connecticut, Georgia, Illinois, Louisiana, Michigan, Minnesota
2026-08-21
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
DrugLenbelintide
AstraZeneca
Phase 3
2,500
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Michigan
2026-08-19
Recruiting
A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
NCT07625215Atrial Fibrillation
Bayer
Phase 2
360
California, Colorado, Massachusetts, Michigan, North Carolina, Texas
2026-08-18
Recruiting
Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
NCT07288489Blood Loss, Surgical, Coagulation Disorder
VarmX B.V.
Phase 3
800
Arizona, California, Colorado, Delaware, Florida, Iowa, Massachusetts, Michigan
2026-08-18
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
NCT07540897Narcolepsy Type 1
DrugAlixorexton
Alkermes, Inc.
Phase 3
150
Florida, Georgia, Michigan, Missouri, North Carolina, Ohio, South Carolina, Texas
2026-08-13
Recruiting
A Study of LY3971297 in Participants With Heart Failure
NCT07547540Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Eli Lilly and Company
Phase 1
90
Michigan, Missouri, North Carolina, Texas
2026-08-11
Recruiting
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
NCT07837973Overweight , Obesity, Adults
DrugALV-100
Alveus Therapeutics, Inc.
Phase 2
220
Alabama, Arizona, California, Florida, Illinois, Louisiana, Michigan, New York
2026-08-10
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
DrugBrenipatide
Eli Lilly and Company
Phase 2
606
Alabama, California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan
2026-08-07
Recruiting
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
NCT07513285Clostridium Difficile Infection Recurrence
Acurx Pharmaceuticals Inc.
Phase 2
20
California, Connecticut, Florida, Georgia, Idaho, Illinois, Massachusetts, Michigan
2026-08-06
Recruiting
A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
NCT07746713Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
100
Florida, Michigan, Utah
2026-08-05
Recruiting
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
NCT07282613Diabetes Mellitus, Type 2
DrugCagriSema
Novo Nordisk A/S
Phase 3
80
Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, New York
2026-08-04
Recruiting
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
NCT07723248Metastatic Castration Resistant Prostate Cancer
DrugsRinzimetostat·Xtandi·Taxotere·Darolutamide
ORIC Pharmaceuticals
Phase 3
600
Florida, Indiana, Michigan, North Carolina, Ohio, South Carolina, Tennessee, Texas
2026-08-03
Recruiting
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
NCT07742735Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)
DrugApraglutide
VectivBio AG
Phase 3
124
California, Colorado, District of Columbia, Florida, Illinois, Kentucky, Michigan, New York
2026-08
Recruiting
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
NCT07751991AML (Acute Myeloid Leukemia)
Charm Therapeutics
Phase 1
40
Michigan
2026-08
Recruiting
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
DrugsMRT-2359·Apalutamide
Monte Rosa Therapeutics, Inc
Phase 2
25
California, Colorado, Kansas, Maryland, Michigan, Nebraska, New Jersey, North Carolina
2026-08
Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
NCT07424833Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Ascentage Pharma Group Inc.
Phase 1
180
California, Florida, Michigan, New Jersey, Texas
2026-08
Not yet open
Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer
NCT07707674Metastatic Pancreatic Cancer
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1
24
Michigan, New York, Ohio, Oklahoma, Tennessee, Texas
2026-07-30
Recruiting
First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors
NCT07700160Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
230
California, Michigan, New York, Texas, Virginia
2026-07-30
Recruiting
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
NCT07733765Alopecia Areata
DrugRitlecitinib
Pfizer
Phase 3
336
California, Florida, Illinois, Indiana, Iowa, Maryland, Michigan, North Carolina
2026-07-30
Recruiting
Study of EVO756 in Adults With Migraine
NCT07616128Migraine
Evommune, Inc.
Phase 2
330
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New Jersey
2026-07-29
Recruiting
A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations
NCT07514858Parkinson's Disease
DrugLu AF28996
H. Lundbeck A/S
Phase 2
150
Michigan, Texas
2026-07-28
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795Colorectal Cancer
DrugsVS-7375·Panitumumab·MFOLFOX6·Cetuximab
Verastem, Inc.
Phase 2
150
California, Florida, Indiana, Michigan, Missouri, New Jersey, New York, Tennessee
2026-07-28
Recruiting
Autus Valve Continued Access Study (CAS)
NCT07466745Congenital Heart Disease
Edwards Lifesciences
Not applicable
36
California, Colorado, Georgia, Massachusetts, Michigan, New York, North Carolina, Ohio
2026-07-27
Recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680Solid Tumors
DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab
Bristol-Myers Squibb
Phase 2
260
California, Colorado, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New York
2026-07-27
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Colorado, Maryland, Michigan, New Jersey, New York, North Carolina, Ohio, Utah
2026-07-24
Recruiting
Repeatable Evaluation of Functional Intra-procedural Signals for Effect in Pulsed Field Ablation REFINE-PFA
NCT07275151Atrial Fibrillation
CathVision ApS
Observational
40
Michigan, New Jersey
2026-07-22
Recruiting
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
NCT07656415Sickle Cell Disease
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 3
159
Indiana, Michigan, Mississippi
2026-07-21
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
Duboce Biopharmaceuticals, Inc.
Phase 1
210
Colorado, Michigan, New Jersey, New York, Tennessee, Texas
2026-07-17
Recruiting
A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors
NCT07703878Solid Tumor
Gilead Sciences
Phase 1
302
Michigan, Texas
2026-07-17
Recruiting
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
NCT07621809Sjögren´s Disease
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
570
Arizona, Florida, Illinois, Massachusetts, Michigan, New York, North Carolina, Oklahoma
2026-07-16
Recruiting
A Trial of CRD-4730 in HFrEF
NCT07750873Heart Failure With Reduced Ejection Fraction (HFrEF)
DrugCRD-4730
Cardurion Pharmaceuticals, Inc.
Phase 2
525
California, Michigan
2026-07-15
Not yet open
Light Utilization COX-Inhibitory Device Therapy for Infant Cardiac Arrest (LUTICA Study). The LUCID Device is Used in the Treatment of Ischemic Brain Reperfusion Injury Caused by Cardiac Arrest in Pediatric Patients.
NCT07556939Reperfusion Injury, Post Cardiac Arrest Brain Injury
Mitovation, Inc
Not applicable
30
Michigan
2026-07-15
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
NCT07683000HIV-1-infection
DrugsTeropavimab·Zinlirvimab·Lenacapavir
Gilead Sciences
Phase 3
590
Michigan, Virginia
2026-07-14
Recruiting
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
NCT07652242Triple Negative Breast Cancer (TNBC)
DrugsOlaparib·Capecitabine·Pembrolizumab
Immunomic Therapeutics, Inc.
Phase 1
60
Michigan, Tennessee
2026-07-14
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
NCT07682961HIV Infections
DrugsTeropavimab·Zinlirvimab·Rilpivirine·Cabotegravir
Gilead Sciences
Phase 3
590
California, Florida, Georgia, Michigan, Missouri, Texas, Virginia, Washington
2026-07-14
Recruiting
REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)
NCT07599904Acute Ischemic Stroke
Medtronic Neurovascular Clinical Affairs
Observational
1,500
Michigan, New York, Texas
2026-07-13
Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
NCT07630974Malignant Neoplasm
DrugIfinatamab Deruxtecan
Merck Sharp & Dohme LLC
Phase 1/2
134
California, Colorado, Iowa, Massachusetts, Michigan, New Jersey, New York, North Dakota
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
900
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2026-07-06
Recruiting
Early Feasibility Study (EFS) of the Nyra Cardiac Leaflet Enhancer (CARLEN) System
NCT07503236Mitral Regurgitation Functional
Nyra Medical, Inc.
Not applicable
30
California, Michigan, Ohio
2026-07-02
Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
NCT07536269Congenital Adrenal Hyperplasia
DrugCrinecerfont
Neurocrine Switzerland GmbH
Phase 2
20
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Michigan, Minnesota
2026-07-01
Recruiting
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07719361Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
Flare Therapeutics Inc.
Phase 1
60
California, Massachusetts, Michigan, New Jersey, South Carolina, Tennessee, Texas
2026-07-01
Recruiting
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
NCT07005180Parkinson Disease
Hillhurst Biopharmaceuticals, Inc.
Phase 2
36
California, Florida, Massachusetts, Michigan, New York, Washington
2026-06-30
Recruiting
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
NCT07614984Lipoprotein(a)
DrugsHRS-5346·Enlicitide
Merck Sharp & Dohme LLC
Phase 2
750
Alabama, California, Connecticut, Florida, Maryland, Michigan, Minnesota, Montana
2026-06-30
Active, closed
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
NCT07662122Obesity, Overweight
DrugBI 3034701
Boehringer Ingelheim
Phase 2
344
Alabama, California, Florida, Georgia, Kentucky, Michigan, Missouri, North Carolina
2026-06-30
Active, closed
Safety of MOON101 for the Treatment of Peanut Allergy
NCT07580898Peanut Allergy
Moonlight Therapeutics, Inc.
Phase 1
40
Arkansas, Georgia, Kansas, Michigan, North Carolina
2026-06-29
Recruiting
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
NCT07508787Renal Transplant Failure and Rejection
DrugsSiplizumab·Rabbit anti-thymocyte globulin·Thymoglobulin
Nefro Avillion Clinical Development, LLC
Phase 2
120
California, Florida, Georgia, Michigan, New Jersey, Texas, Washington
2026-06-29
Recruiting
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
NCT07661056Graves Disease
DrugBHV-1300
Biohaven Therapeutics Ltd.
Phase 3
300
Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Michigan
2026-06-26
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916HIV Infections
DrugsCab Ula·Rpv La·Cabotegravir
ViiV Healthcare
Phase 3
564
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Maryland, Michigan
2026-06-25
Recruiting
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
NCT07511361Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Kardigan, Inc.
Phase 2
140
Colorado, Florida, Illinois, Michigan, New York, Ohio, South Carolina, Tennessee
2026-06-23
Recruiting
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
NCT07406633GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour
DrugsKQB198·Imatinib
Kumquat Biosciences Inc.
Phase 2
46
California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, New York
2026-06-23
Recruiting
Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis
NCT07122518Pulmonary Artery Stenosis
Cordis US Corp.
Observational
35
California, Georgia, Michigan, Missouri, Nebraska, Ohio, Pennsylvania, Texas
2026-06-23
Recruiting
Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)
NCT07062471Carotid Artery Calcification, Carotid Artery Diseases
Shockwave Medical, Inc.
Not applicable
185
Arkansas, California, District of Columbia, Florida, Illinois, Massachusetts, Michigan, Minnesota
2026-06-22
Recruiting
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07581184Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC
Aktis Oncology, Inc.
Phase 1
138
California, Florida, Kansas, Massachusetts, Michigan, Nebraska
2026-06-17
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
DrugsVS-7375·Cetuximab
Verastem, Inc.
Phase 2
180
California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey
2026-06-16
Recruiting
A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)
NCT07606274LMNA-Related Dilated Cardiomyopathy
Nuevocor Pte. Ltd.
Phase 1/2
21
Alabama, California, Massachusetts, Michigan, Minnesota, Ohio, Texas
2026-06-16
Recruiting
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
NCT07645287HIV-1-infection
DrugsGS-3242·B/F/TAF·Lenacapavir
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Recruiting
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
NCT07309445Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Observational
150
Alabama, Arkansas, California, Colorado, Florida, Illinois, Indiana, Michigan
2026-06-12
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2/3
500
California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey, North Carolina
2026-06-11
Recruiting
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
NCT07595549Obesity, Overweight and/or Obesity, Overweight
DrugBerobenatide
Pfizer
Phase 3
954
California, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan, Nebraska
2026-06-10
Recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
NCT07570316Graves' Disease, Graves Disease
DrugEfgartigimod PH20
argenx
Phase 3
230
California, Florida, Kansas, Michigan, Missouri, New York, Texas
2026-06-10
Recruiting
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
NCT07682896Graves' Disease
Yarrow Bioscience, Inc.
Phase 2
232
Arizona, California, Florida, Georgia, Kentucky, Michigan, Nebraska, New York
2026-06-10
Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
DrugsArsenic Trioxide·ATRA
Quetzal Therapeutics
Phase 3
150
Alabama, California, Georgia, Kentucky, Maryland, Michigan, New York, North Carolina
2026-06-08
Recruiting
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
NCT07448038Atherosclerosis
Genentech, Inc.
Phase 2
162
California, Connecticut, Florida, Indiana, Michigan, Minnesota, Missouri, Nebraska
2026-06-05
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Recruiting
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
NCT07645820Atopic Dermatitis
Castle Biosciences Incorporated
Observational
450
Arizona, Maryland, Michigan, Missouri, Nevada, New Hampshire, Texas, Virginia
2026-06-04
Recruiting
Study of ALK-001 on the Progression of Stargardt Disease
NCT07419334Stargardt Disease
DrugALK-001
Alkeus Pharmaceuticals, Inc.
Phase 3
230
Arizona, Colorado, Florida, Massachusetts, Michigan, Ohio, Pennsylvania, Texas
2026-06-03
Recruiting
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
NCT07519902Persistent Corneal Epithelial Defect
DrugCenegermin
Dompé Farmaceutici S.p.A
Phase 3
150
California, Florida, Massachusetts, Michigan, Missouri, New York, North Carolina, South Dakota
2026-06-02
Recruiting
Study of GS-2426 in Participants With Advanced Solid Tumors
NCT07601243Advanced Solid Tumors
Gilead Sciences
Phase 1
174
Michigan, New Jersey, New York, Texas
2026-06-02
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Recruiting
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
NCT07613294Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
252
California, Florida, Idaho, Massachusetts, Michigan, Nevada, Pennsylvania, Utah
2026-06-01
Recruiting
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
R1 Therapeutics
Phase 2
168
Alabama, California, Colorado, Connecticut, Florida, Georgia, Michigan, Minnesota
2026-06-01
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
California, Colorado, Connecticut, Illinois, Iowa, Kansas, Massachusetts, Michigan
2026-05-28
Recruiting
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
NCT07623668Optic Neuritis
DrugMethylprednisolone
Oculis
Phase 3
210
Michigan, South Carolina, Texas
2026-05-28
Recruiting
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
NCT07609914Acute Treatment of Migraine
DrugRimegepant
Pfizer
Phase 4
400
California, Florida, Indiana, Massachusetts, Michigan, Minnesota, Mississippi, Nevada
2026-05-28
Recruiting
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266Polycythemia Vera
Ono Pharmaceutical Co., Ltd.
Phase 3
250
Florida, Georgia, Maryland, Michigan, New York, Ohio
2026-05-25
Recruiting
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
NCT07599982Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
DreaMed Diabetes
Not applicable
102
Maryland, Michigan, New York, North Carolina, Texas, Utah
2026-05-25
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
460
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-22
Recruiting
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
NCT07531745Dravet Syndrome
Ionis Pharmaceuticals, Inc.
Phase 1/2
32
Michigan, Minnesota, North Carolina, Tennessee, Washington
2026-05-21
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282High Risk Smoldering Multiple Myeloma (HR-SMM)
DrugsLinvoseltamab·Darzalex·Daratumumab
Regeneron Pharmaceuticals
Phase 3
270
Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio
2026-05-21
Recruiting
A Study of LY3439539 in Participants With Alzheimer's Disease
NCT07598370Alzheimer Disease
Eli Lilly and Company
Phase 1
30
California, Florida, Michigan
2026-05-21
Recruiting
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
NCT07633470Alzheimer Disease
Alpha Cognition, Inc
Phase 4
150
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2026-05-20
Not yet open
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsNNC0487-0111·Semaglutide
Novo Nordisk A/S
Phase 3
1,000
Florida, Georgia, Idaho, Maryland, Michigan, Texas, Virginia
2026-05-20
Recruiting
AtraUmatic Laparoscopic HerNia Repair Clinical Investigation to Evaluate the Safety and Performance of The ECLIPSIUM System for Mesh Fixation IDE
NCT07277946Hernia
Tissium
Not applicable
240
California, Florida, Illinois, Kentucky, Michigan, Nebraska, North Carolina, Ohio
2026-05-14
Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
NCT07579702Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Insulet Corporation
Not applicable
200
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Massachusetts, Michigan
2026-05-13
Recruiting
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
NCT07572006Hematologic Neoplasms
Janssen Research & Development, LLC
Phase 1
360
Indiana, Michigan, New Jersey, New York, Tennessee, Texas
2026-05-13
Recruiting
CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material
NCT07276711Aortic Valve Stenosis, Aortic Stenosis, Aortic Valve Disease
EmStop Inc
Not applicable
663
California, Florida, Louisiana, Michigan, North Carolina, South Dakota, Texas
2026-05-12
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of ION775
NCT07604974Hypertriglyceridemia, Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc.
Phase 2
72
California, Colorado, Florida, Georgia, Indiana, Kentucky, Michigan, Ohio
2026-05-12
Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
NCT07539311Gastrointestinal Cancers
DrugRina-S
Genmab
Phase 2
160
Michigan, Texas
2026-05-11
Recruiting
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
NCT07265674Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
J-Pharma Co., Ltd.
Phase 3
480
California, Florida, Illinois, Kentucky, Louisiana, Michigan, Minnesota, Nevada
2026-05-11
Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
NCT07296744Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Supira Medical
Not applicable
358
California, Georgia, Illinois, Michigan, Minnesota, Missouri, New Jersey, New York
2026-05-11
Recruiting
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
NCT07406360Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
GlaxoSmithKline
Phase 3
1,209
Alabama, California, Florida, Georgia, Illinois, Michigan, Ohio, South Carolina
2026-05-11
Recruiting
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
NCT07543120Hypertension (HTN)
DrugQCZ484
Novartis Pharmaceuticals
Phase 2
323
California, Florida, Georgia, Illinois, Kansas, Maryland, Michigan, Missouri
2026-05-07
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Arizona, California, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota
2026-05-06
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412Metastatic Colorectal Cancer
DrugsTrifluridine/Tipiracil·Bevacizumab
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Colorado, Florida, Illinois, Michigan, Minnesota, Missouri, New York, Tennessee
2026-05-06
Recruiting
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110Metastatic Castration-resistant Prostate Cancer
DrugsXofigo·FPI-2265·Cabazitaxel·Zytiga
AstraZeneca
Phase 3
670
Alabama, Arizona, California, Colorado, Florida, Illinois, Louisiana, Michigan
2026-05-04
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
DrugXNW27011
Astellas Pharma Global Development, Inc.
Phase 1/2
150
Alabama, California, Florida, Georgia, Indiana, Michigan, New Jersey, New York
2026-05-04
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073Colitis, Ulcerative, Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
NCT07580716Primary Knee Osteoarthritis
DrugAllocetra
Enlivex Therapeutics Ltd.
Phase 2
270
Florida, Louisiana, Michigan
2026-05-01
Recruiting
A Study of VV-14305 for the Treatment of Thyroid Eye Disease
NCT07404111Thyroid Eye Disease (TED)
Kriya Therapeutics, Inc.
Phase 1/2
135
Michigan, Nevada, Pennsylvania
2026-05-01
Recruiting
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
NCT07490301Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
DrugsTelisotuzumab Adizutecan·Fluorouracil·Irinotecan·Oxaliplatin
AbbVie
Phase 2/3
900
Connecticut, Illinois, Michigan, Missouri, Ohio, Pennsylvania, Texas, Virginia
2026-04-30
Recruiting
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
NCT07446322Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
DrugsPelareorep·Folfiri·Avastin·Bevacizumab
Oncolytics Biotech
Phase 2
60
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Michigan
2026-04-30
Recruiting
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
NCT07469891Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis
Prelude Therapeutics Incorporated
Phase 1
100
California, Colorado, Florida, Michigan, Pennsylvania, Tennessee, Texas
2026-04-29
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
590
District of Columbia, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina, Ohio
2026-04-23
Recruiting
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
NCT07596901Myasthenia Gravis, Generalized
Aurinia Pharmaceuticals Inc.
Phase 1/2
81
California, Florida, Illinois, Michigan, Texas
2026-04-22
Recruiting
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
NCT07489651Generalized Anxiety Disorder
DrugRE104
Reunion Neuroscience Inc
Phase 2
160
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Michigan
2026-04-20
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
DrugBI 3000202
Boehringer Ingelheim
Phase 2
405
California, Colorado, Florida, Michigan, Mississippi, Montana, North Carolina, Ohio
2026-04-20
Recruiting
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07509307Obesity, Overweight, Osteoarthritis, Knee
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Florida, Illinois, Kentucky, Michigan, Missouri, New York
2026-04-20
Recruiting
EVERO Drug-coated Balloon (DCB) Randomized Trial
NCT07144150Peripheral Vascular Disease, Peripheral Arterial Disease
Cook Research Incorporated
Not applicable
410
Connecticut, Florida, Iowa, Michigan, Mississippi, New Jersey, South Carolina, Texas
2026-04-17
Recruiting
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
NCT07264959Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Observational
150
Colorado, Illinois, Maryland, Massachusetts, Michigan, Missouri, Utah
2026-04-15
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Arizona, California, Florida, Georgia, Indiana, Massachusetts, Michigan, New Hampshire
2026-04-14
Recruiting
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT07533006Alopecia Areata
DrugLY4005130
Eli Lilly and Company
Phase 2
60
California, Florida, Massachusetts, Michigan, New Hampshire, Texas, Utah
2026-04-14
Recruiting
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06769698Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugCemiplimab
Regeneron Pharmaceuticals
Phase 2
120
California, Florida, Georgia, Illinois, Kentucky, Michigan, Nebraska, New York
2026-04-14
Recruiting
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
NCT07387068Advanced Solid Tumors
Genmab
Phase 1
121
Connecticut, Michigan, New York
2026-04-07
Active, closed
A Pivotal Study to Evaluate the Clinical Benefit, Performance and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults
NCT07287124Hearing Loss, Bilateral Sensorineural
Cochlear
Not applicable
56
Colorado, Florida, Iowa, Michigan, Minnesota, Missouri, New York, Ohio
2026-04-03
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
NCT07430956Atrial Fibrillation (AF)
DrugsAmrecibart·Cenvacibart
Regeneron Pharmaceuticals
Phase 3
2,628
Alabama, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan
2026-04-03
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Florida, Maryland, Michigan, Missouri, Nevada
2026-04-02
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT07355218Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
California, Florida, Indiana, Louisiana, Michigan, North Carolina, Texas
2026-04-01
Recruiting
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
NCT07524946Acne Vulgaris
Bausch Health Americas, Inc.
Phase 4
100
Arkansas, California, Florida, Kentucky, Michigan, Nevada, New York, North Carolina
2026-04-01
Not yet open
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
NCT07227285Urinary Bladder, Overactive, Spinal Cord Injury
DrugEG110A
Cyllene Therapeutics
Phase 1/2
16
California, Michigan, Pennsylvania, Texas
2026-04
Recruiting
Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)
NCT07357428Amyotrophic Lateral Sclerosis, Neuromuscular Disease, Stroke, Tetraplegia/Tetraparesis
Paradromics
Not applicable
2
California, Massachusetts, Michigan
2026-03-31
Recruiting
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
NCT07499674Lung Cancer, Lung Metastases
Vergent Bioscience, Inc.
Phase 3
132
California, Colorado, Florida, Michigan, Minnesota, Pennsylvania, Texas
2026-03-31
Recruiting
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT07454642Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
Avacta Life Sciences Ltd
Phase 1
174
Arizona, Florida, Illinois, Michigan, New York, Texas, Virginia
2026-03-31
Recruiting
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647Schizophrenia
DrugML-007C-MA
MapLight Therapeutics
Phase 2
500
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2026-03-31
Recruiting
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
NCT07199465Cytomegalovirus Prophylaxis
DrugLetermovir
Merck Sharp & Dohme LLC
Phase 1
40
Alabama, California, Colorado, Florida, Georgia, Illinois, Michigan, Minnesota
2026-03-30
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Arizona, Arkansas, California, Florida, Illinois, Indiana, Maryland, Michigan
2026-03-27
By invitation
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
NCT07338968Choroidal Melanoma, Indeterminate Lesions
Aura Biosciences
Observational
100
California, Michigan, Minnesota, Oklahoma, South Carolina, Tennessee, Texas, Utah
2026-03-27
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351Advanced Renal Cell Carcinoma (RCC)
DrugsCasdatifan·Pumitamig·Cabozantinib·Yervoy
Bristol-Myers Squibb
Phase 1/2
474
California, Connecticut, District of Columbia, Florida, Indiana, Iowa, Maryland, Michigan
2026-03-26
Recruiting
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
NCT07493265Narcolepsy
DrugE2086
Eisai Inc.
Phase 2
64
California, Florida, Georgia, Maryland, Michigan, North Carolina, South Carolina, Texas
2026-03-26
Recruiting
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
NCT07144319Bladder Cancer, Non-muscle Invasive Bladder Cancer
Photocure
Observational
500
Florida, Michigan, New Jersey
2026-03-25
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
DrugApecotrep
Boehringer Ingelheim
Phase 2
132
Alabama, California, Colorado, Florida, Illinois, Maryland, Michigan, New York
2026-03-23
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019Secondary Progressive Multiple Sclerosis
DrugOrelabrutinib
Zenas BioPharma (USA), LLC
Phase 3
990
Arizona, California, Florida, Indiana, Kansas, Massachusetts, Michigan, Missouri
2026-03-23
Recruiting
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms
DrugsBelzutifan·Cabozantinib·Lenvatinib·Nivolumab
Merck Sharp & Dohme LLC
Phase 3
450
Massachusetts, Michigan, Pennsylvania, Tennessee, Texas, Washington
2026-03-23
Recruiting
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07474792Plaque Psoriasis
DrugORKA-002
Oruka Therapeutics, Inc.
Phase 2
160
Alabama, Arizona, California, Connecticut, Florida, Illinois, Massachusetts, Michigan
2026-03-19
Recruiting
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
NCT07118358Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Biotronik, Inc.
Not applicable
325
California, Colorado, Florida, Kentucky, Michigan, Minnesota, Missouri, New York
2026-03-16
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
DrugsPumitamig·Yervoy·Ipilimumab
Bristol-Myers Squibb
Phase 1/2
198
California, Illinois, Michigan, New Jersey, New York, Oregon, Tennessee, Washington
2026-03-16
Recruiting
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
NCT07500090Idiopathic Hypersomnia
DrugPitolisant
Harmony Biosciences Management, Inc.
Phase 3
248
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Michigan
2026-03-16
Recruiting
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT07470853PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
DrugBevacizumab
Whitehawk Therapeutics, Inc.
Phase 1
265
Arkansas, California, Florida, Illinois, Michigan, New York, North Carolina, Ohio
2026-03-15
Recruiting
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
NCT07220785Generalized Lipodystrophy
DrugMibavademab
Regeneron Pharmaceuticals
Phase 3
28
Michigan, Texas
2026-03-13
Recruiting
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
NCT07412470Kidney Transplant Rejection
DrugsRabbit anti-thymocyte globulin·Frexalimab·Mycophenolate Mofetil·Tacrolimus
Sanofi
Phase 2/3
526
Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan, New York, Ohio
2026-03-13
Recruiting
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
NCT07475806Muscle-invasive Bladder Cancer
DrugsEnfortumab Vedotin·Pembrolizumab
Astellas Pharma Global Development, Inc.
Phase 2
240
Arkansas, Illinois, Indiana, Michigan, New Jersey, New York, Pennsylvania, South Carolina
2026-03-12
Recruiting
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
NCT07481383Pancreatic Adenocarcinoma Non-resectable
Continuity Biosciences, LLC
Phase 1
12
Michigan, West Virginia
2026-03-11
Active, closed
Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support (VR-CARES)
NCT07430371Direct Care Workers, Dementia Caregiver, In-Home Care, Caregiver Social Support
Rendever, Inc.
Not applicable
30
California, Massachusetts, Michigan, Texas
2026-03-11
Recruiting
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
NCT07339111Knee Cartilage Defects
Medipost, Inc.
Phase 3
300
Alabama, Arizona, California, Colorado, Illinois, Kentucky, Louisiana, Michigan
2026-03-11
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
California, Florida, Georgia, Michigan, Texas
2026-03-10
Recruiting
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors, NRAS Mutation, NRAS G12D
Relay Therapeutics, Inc.
Phase 1
35
California, Colorado, Massachusetts, Michigan, New York, Tennessee, Virginia
2026-03-09
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Arizona, California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Nevada
2026-03-09
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177Non-segmental Vitiligo
DrugGIA632
Novartis Pharmaceuticals
Phase 2
210
Alabama, California, Florida, Indiana, Michigan, Nebraska, Nevada, New York
2026-03-09
Recruiting
Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)
NCT07277582Long QT Syndrome (LQTS) 2
Thryv Therapeutics, Inc.
Phase 2/3
84
Arizona, California, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2026-03-07
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
600
California, Colorado, Florida, Georgia, Illinois, Louisiana, Michigan, New Jersey
2026-03-05
Recruiting
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
NCT07615426Schizophrenia
Janssen Research & Development, LLC
Phase 1
64
California, Georgia, Illinois, Michigan, New York, Texas
2026-03-02
Recruiting
ASV Therapy for Insomnia
NCT07011966Insomnia, Insomnia (Moderate)
ResMed
Not applicable
25
Michigan
2026-03-01
Recruiting
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
NCT07250724Clostridioides Difficile Infection Recurrence
Bactolife A/S
Observational
60
Georgia, Michigan, Minnesota, Wisconsin
2026-03-01
Recruiting
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
NCT07409246Multiple Myeloma
AbbVie
Phase 1
127
California, Colorado, Florida, Georgia, Illinois, Michigan
2026-02-27
Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Observational
1,500
Arkansas, California, Florida, Georgia, Illinois, Michigan, Minnesota, Nebraska
2026-02-26
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
Colorado, Florida, Michigan, New York, Tennessee, Texas, Utah, Virginia
2026-02-24
Recruiting
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
NCT07051707COPD, Chronic Obstructive Pulmonary Disease
Nuvaira, Inc.
Not applicable
200
Alabama, Florida, Michigan, North Carolina, Ohio, Pennsylvania, Virginia, Wisconsin
2026-02-24
Recruiting
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
NCT07189871Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
Radiopharm Theranostics, Ltd
Phase 1/2
61
Alabama, Michigan, Nebraska, Texas
2026-02-23
Recruiting
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
NCT07425574Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Astellas Pharma Global Development, Inc.
Observational
90
Arizona, California, Florida, Illinois, Michigan, Mississippi, North Carolina, Ohio
2026-02-20
Recruiting
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
NCT07047690Systemic Sclerosis
DrugNemolizumab
Galderma R&D
Phase 2
162
Michigan, Texas
2026-02-20
Recruiting
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
NCT07409103Active Rheumatoid Arthritis
Elevara Medicines Limited
Phase 2
180
Arizona, California, Colorado, Florida, Louisiana, Michigan, North Carolina, Pennsylvania
2026-02-18
Recruiting
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
DrugsCemsidomide·Dexamethasone
C4 Therapeutics, Inc.
Phase 2
100
Alabama, Arizona, California, Florida, Georgia, Indiana, Iowa, Michigan
2026-02-18
Recruiting
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07335497Locally Advanced / Metastatic Solid Tumors
Crescent Biopharma, Inc.
Phase 1/2
290
Alabama, California, Colorado, District of Columbia, Florida, Michigan, New York, Ohio
2026-02-17
Recruiting
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
NCT07465835T Cell Malignancies
DrugELA026
Electra Therapeutics Inc.
Phase 1
84
Connecticut, Georgia, Michigan, New York, Ohio, Texas
2026-02-17
Not yet open
Clinical Evaluation of Radiation Reduction for Optimized Safety
NCT06348875Coronary Artery Disease, Myocardial Infarction, Coronary Disease, Coronary Stenosis
Angiowave Imaging
Observational
50
Michigan
2026-02-15
Recruiting
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07491458MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugHU6
Rivus Pharmaceuticals, Inc.
Phase 2
180
Arizona, Arkansas, California, Florida, Illinois, Louisiana, Michigan, Minnesota
2026-02-13
Recruiting
Aspiration Thrombectomy Using the Symphony or Prodigy System
NCT07350499Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
Imperative Care, Inc.
Observational
750
Alabama, Florida, Illinois, Indiana, Michigan, New York, Ohio, Virginia
2026-02-13
Recruiting
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
NCT07215273Invasive Mould Infection
DrugVoriconazole
Elion Therapeutics, Inc.
Phase 2
60
Alabama, California, Georgia, Maryland, Massachusetts, Michigan, Missouri, Texas
2026-02-13
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
800
Alabama, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2026-02-10
Recruiting
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702Sepsis, Acute Kidney Injury
DrugAZD4144
AstraZeneca
Phase 2
124
Arizona, California, Kansas, Maryland, Massachusetts, Michigan, New York, North Carolina
2026-02-10
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
80
California, Colorado, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2026-02-10
Recruiting
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
NCT07332455Neoplasms, Prostate
GlaxoSmithKline
Phase 1/2
54
California, Michigan, Pennsylvania, Utah
2026-02-10
Recruiting
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
NCT07201129Nephritis, Lupus, Lupus Erythematosus, Systemic
DrugCenerimod
Viatris Innovation GmbH
Phase 3
300
Florida, Michigan, Texas
2026-02-09
Recruiting
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
NCT07213830Advanced Solid Tumor, Metastatic Solid Tumor
Ipsen
Phase 1/2
102
Michigan, Tennessee, Texas
2026-02-06
Recruiting
Evaluating Screening Adherence Between Moment for Parents App and Attention Control
NCT07322042Mental Health Screening Adherence
Poisera, Inc.
Not applicable
160
Michigan
2026-02-05
Recruiting
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07325136Relapsed/Refractory Small Cell Lung Cancer
DrugPumitamig
Bristol-Myers Squibb
Phase 1/2
240
Michigan, New York, North Carolina, Ohio, Tennessee
2026-02-03
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Alabama, California, Colorado, Connecticut, Florida, Indiana, Kansas, Michigan
2026-02-02
Recruiting
Study to Evaluate the REMEDY SPECTRUM GV IM Spacer Nail in the Treatment of Ankle-Related Infections
NCT06428448Periprosthetic Joint Infection
OsteoRemedies, LLC
Phase 2
60
Michigan, North Carolina
2026-02-01
Recruiting
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
NCT07422675PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
Serina Therapeutics
Phase 1
40
Colorado, Florida, Michigan
2026-02-01
Active, closed
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
NCT07363720Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
DrugTAK-861
Takeda
Phase 3
98
California, Florida, Michigan, New Jersey, North Carolina, Ohio, South Carolina, Texas
2026-01-29
Recruiting
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07259317Adenocarcinoma, Carcinoma, Pancreatic Ductal
DrugsRelacorilant·Nab-paclitaxel·Gemcitabine
Corcept Therapeutics
Phase 2
80
Arizona, California, Florida, Georgia, Indiana, Kansas, Michigan, Minnesota
2026-01-27
Recruiting
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263Hidradenitis Suppurativa
DrugZasocitinib
Takeda
Phase 2
90
Arizona, Arkansas, California, Florida, Massachusetts, Michigan, New Hampshire, New York
2026-01-26
Recruiting
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07287917Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
DrugsDifluoromethylornithine·DFMO·Capivasertib·Fulvestrant
Aminex Therapeutics, Inc.
Phase 1/2
92
Arizona, California, Colorado, Kansas, Michigan, Minnesota, New York, Ohio
2026-01-26
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190Uveal Melanoma
DrugDarovasertib
IDEAYA Biosciences
Phase 3
520
Arizona, California, Colorado, Florida, Maryland, Massachusetts, Michigan, Minnesota
2026-01-25
Active, closed
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415Obesity, Overweight
DrugRetatrutide
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Hawaii, Kentucky, Massachusetts, Michigan, New York
2026-01-24
Recruiting
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
NCT07494305Bipolar I Disorder
DrugLB-102
LB Pharmaceuticals Inc.
Phase 2
320
Arkansas, California, Florida, Georgia, Illinois, Michigan, Missouri, Nevada
2026-01-23
Recruiting
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
NCT07230288Idiopathic Pulmonary Fibrosis
AbbVie
Phase 2
165
Alabama, Florida, Illinois, Michigan, Missouri, Pennsylvania, Virginia
2026-01-23
Recruiting
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring
Phase 2
84
Arizona, California, Florida, Indiana, Louisiana, Maryland, Michigan, Minnesota
2026-01-22
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
California, Illinois, Massachusetts, Michigan, Minnesota, New Jersey, New York, Pennsylvania
2026-01-22
Active, closed
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860Dermatitis, Atopic
Janssen Research & Development, LLC
Phase 2
189
California, Florida, Illinois, Indiana, Michigan, North Dakota, Oregon, Pennsylvania
2026-01-20
Recruiting
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
NCT07263594Gastrointestinal Cancer
DualityBio Inc.
Phase 1/2
127
Florida, Michigan, North Carolina, Ohio
2026-01-20
Recruiting
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
NCT07348692Pneumococcal Immunization, Healthy Volunteers
DrugsPCV21 vaccine·Prevnar 20
Sanofi
Phase 3
2,195
Arkansas, California, Florida, Kentucky, Michigan, New York, South Carolina, Texas
2026-01-20
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
NCT07359846Severe Asthma
DrugGB-0895
Generate Biomedicines
Phase 3
786
California, Florida, Massachusetts, Michigan, New York, Ohio, Oklahoma, South Carolina
2026-01-20
Recruiting
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
NCT07276373Neoplasms
DrugNivolumab
Corcept Therapeutics
Phase 1/2
50
California, Illinois, Michigan, Texas, Utah
2026-01-16
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07185009Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
751
Arizona, California, Colorado, Florida, Indiana, Louisiana, Michigan, Missouri
2026-01-16
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
NCT07321106Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC
Cartography Biosciences
Phase 1
80
Arizona, California, Florida, Georgia, Michigan, Texas, Virginia
2026-01-15
Recruiting
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
NCT06980480Multiple Myeloma, Secondary Immunodeficiency
Takeda
Phase 3
183
Alabama, California, Kansas, Maryland, Michigan, Missouri, New York
2026-01-14
Active, closed
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
NCT07365826Pneumococcal Vaccines
Drug31-valent pneumococcal conjugate vaccine
Vaxcyte, Inc.
Phase 3
1,390
Arizona, Colorado, Florida, Indiana, Kansas, Kentucky, Michigan, Nebraska
2026-01-12
Recruiting
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
NCT07226427Platinum-resistant Ovarian Cancer
Stemline Therapeutics, Inc.
Phase 1
100
Arkansas, Connecticut, Florida, Massachusetts, Michigan, Minnesota, Virginia
2026-01-10
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1
27
Arizona, California, Illinois, Michigan, Missouri, New York, North Carolina, Washington
2026-01-09
Active, closed
Study of VYD2311 for the Prevention of COVID-19
NCT07298434COVID-19
Invivyd, Inc.
Phase 3
1,770
California, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2026-01-08
Recruiting
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
NCT07195916Solid Tumors, Hematologic Malignancies
Incyte Corporation
Phase 1
280
California, Michigan, Nebraska, New York, Tennessee, Texas
2026-01-08
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 1
574
Connecticut, Maryland, Massachusetts, Michigan, New York, Texas, Virginia
2026-01-08
Recruiting
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
NCT07223697Atopic Dermatitis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
120
California, Florida, Georgia, Michigan, Pennsylvania
2026-01-08
Recruiting
The ArtixASCEND Study
NCT07135895Acute Lower Limb Arterial Occlusion
Inari Medical
Not applicable
250
California, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan, New Jersey
2026-01-07
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
NCT07219043Microvascular Inflammation
DrugFelzartamab
Biogen
Phase 2
81
California, Colorado, Kansas, Michigan, Minnesota, Missouri, Nebraska, New Jersey
2026-01-05
Recruiting
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
NCT07282587Advanced Pheochromocytoma and Paraganglioma, PCPG
DrugONC206
Jazz Pharmaceuticals
Phase 2
90
California, Colorado, Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah
2026-01-02
Recruiting
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
NCT07157033Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma
Phase 1/2
36
California, Michigan, New Mexico, Texas
2026-01-01
Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
Cogent Biosciences, Inc.
Phase 1
100
Arizona, Connecticut, Florida, Illinois, Louisiana, Michigan, Minnesota, Missouri
2025-12-30
Active, closed
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
NCT07226622Wilson Disease
Prime Medicine, Inc.
Observational
30
California, Connecticut, Illinois, Massachusetts, Michigan, Texas
2025-12-29
Active, closed
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660Atopic Dermatitis
DrugGalvokimig
UCB Biopharma SRL
Phase 2
165
California, Florida, Georgia, Illinois, Indiana, Kentucky, Michigan, Nebraska
2025-12-29
Recruiting
Diagnosing Epilepsy To EffeCT Change
NCT07110337Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Not applicable
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Michigan
2025-12-23
Recruiting
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
NCT07333183Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
20
California, Florida, Illinois, Kansas, Massachusetts, Michigan, New Mexico, North Carolina
2025-12-23
Recruiting
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT07318805Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
DrugsEnlituo·Zirabev·Erbitux·Avastin
Pfizer
Phase 1
260
California, Michigan, New York, Texas, Utah
2025-12-23
Recruiting
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
NCT07258836Neoplasms, Healthy
Eli Lilly and Company
Phase 1
41
Connecticut, Massachusetts, Michigan, New York
2025-12-22
Recruiting
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
NCT07280156Gout
DrugMethotrexate
Protalix
Phase 2
150
Arizona, Arkansas, California, Florida, Georgia, Michigan, Pennsylvania, Texas
2025-12-22
Active, closed
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
360
Alaska, California, District of Columbia, Florida, Georgia, Illinois, Michigan, New Jersey
2025-12-22
Recruiting
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
NCT07265947Low Grade Upper Tract Urothelial Carcinoma
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
230
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2025-12-22
Recruiting
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
NCT07300241Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
Neomorph, Inc
Phase 1
30
California, Connecticut, Florida, Illinois, Michigan, Nebraska, New York, Ohio
2025-12-19
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT07294170Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis
DrugsEmpasiprubart·Efgartigimod
argenx
Observational
70
California, Florida, Massachusetts, Michigan, Nevada, New York, North Carolina, Ohio
2025-12-19
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT07284420AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
DrugsEmpasiprubart·Efgartigimod
argenx
Phase 2
70
California, Florida, Massachusetts, Michigan, Nevada, New York, North Carolina, Ohio
2025-12-19
Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
Whitehawk Therapeutics, Inc.
Phase 1
226
Arkansas, California, Illinois, Michigan, New Jersey, New York, Ohio, Texas
2025-12-19
Recruiting
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
NCT07266831Human Immunodeficiency Virus Type 1 (HIV-1) Infection
DrugB/F/TAF
Merck Sharp & Dohme LLC
Phase 2/3
570
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2025-12-18
Recruiting
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
NCT07266428Advanced Solid Tumors
Ottimo Pharma Limited
Phase 1/2
170
Connecticut, Massachusetts, Michigan, Texas, Utah
2025-12-17
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
DrugFurmonertinib
ArriVent BioPharma, Inc.
Phase 3
480
California, Colorado, Illinois, Michigan, New York, Ohio, Pennsylvania, Texas
2025-12-17
Recruiting
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
NCT06956690Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
Hummingbird Bioscience
Phase 1/2
180
California, Indiana, Michigan, Texas
2025-12-17
Recruiting
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639Hemoglobinopathy, Sickle Cell Disease
Beam Therapeutics Inc.
Observational
50
Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2025-12-15
Recruiting
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
NCT07293754Advanced Malignant Solid Tumor
Repertoire Immune Medicines
Phase 1/2
150
Michigan, New York, Texas
2025-12-12
Recruiting
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
NCT07221474Squamous Non-small Cell Lung Cancer
DrugsIntismeran autogene·Nab-paclitaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 2
180
Florida, Michigan, Missouri, New Jersey, New York, Ohio, Oregon, Tennessee
2025-12-12
Recruiting
NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study
NCT06604884Intracranial Aneurysm
Medtronic Neurovascular Clinical Affairs
Observational
118
Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri, South Carolina
2025-12-12
Recruiting
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
NCT06922539Small Cell Lung Cancer
DrugFenretinide
SciTech Development, Inc.
Phase 1
44
California, Michigan
2025-12-11
Recruiting
Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia
NCT07226648Fibromyalgia
SPIRE Therapeutics Inc.
Not applicable
180
Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah, West Virginia
2025-12-11
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Minnesota
2025-12-11
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559Breast Cancer, Metastatic
DrugsEvorpacept·Eribulin·Herceptin·Vinorelbine
ALX Oncology Inc.
Phase 2
120
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Michigan, Minnesota
2025-12-10
Recruiting
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
NCT07290036Psoriatic Arthritis, Axial Spondyloarthritis
UCB Biopharma SRL
Phase 1
392
Arizona, California, Colorado, Florida, Illinois, Michigan, New Jersey, New Mexico
2025-12-10
Recruiting
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
NCT07172893Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
HealthTech Wound Care
Phase 4
150
Florida, Michigan, North Carolina, Ohio, Texas, Virginia
2025-12-10
Recruiting
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
NCT07287033Peanut Allergies
Mabylon AG
Phase 1
48
Arkansas, Colorado, Florida, Massachusetts, Michigan, Texas
2025-12-06
Recruiting
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
NCT07137598Rheumatoid Arthritis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
160
Arizona, California, Florida, Illinois, Louisiana, Michigan, New York, Ohio
2025-12-05
Recruiting
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
NCT07213817Locally Advanced Solid Tumor, Metastatic Solid Tumor
Ipsen
Phase 1/2
114
Connecticut, Michigan, Pennsylvania, Texas, Virginia
2025-12-05
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
DrugsCalderasib·Cetuximab
Merck Sharp & Dohme LLC
Phase 2
150
Maryland, Michigan, Nevada, New Jersey, Utah, Virginia
2025-12-04
Recruiting
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07244341Metastatic Castration-resistant Prostate Cancer
DrugsValemetostat·Darolutamide
Daiichi Sankyo
Phase 1
60
California, Massachusetts, Michigan, New York, South Carolina, Texas, Virginia, Wisconsin
2025-12-03
Recruiting
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
NCT07268638Focal Segmental Glomerulosclerosis
Akebia Therapeutics
Phase 2
60
California, Colorado, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-12-03
Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
NCT07260877Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus)
Ventus Therapeutics U.S., Inc.
Phase 2
24
California, Florida, Indiana, Michigan, Missouri, New Mexico, New York, Tennessee
2025-12-03
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724Severe Asthma
DrugGB-0895
Generate Biomedicines
Phase 3
786
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Mississippi
2025-12-03
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Arizona, California, Florida, Georgia, Maryland, Massachusetts, Michigan, Minnesota
2025-12-02
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
NCT07196644Solid Tumors Harboring MET Amplification
DrugTelisotuzumab Adizutecan
AbbVie
Phase 2
100
California, Connecticut, Florida, Illinois, Michigan, New York, North Carolina, Tennessee
2025-12-01
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Alabama, Arizona, California, Florida, Indiana, Michigan, Minnesota, Nebraska
2025-11-27
Recruiting
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc.
Phase 1/2
150
Arizona, California, Colorado, Connecticut, Georgia, Kentucky, Louisiana, Michigan
2025-11-26
By invitation
Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
NCT07450664Prader-Willi Syndrome
Soleno Therapeutics, Inc.
Observational
200
Arizona, California, Colorado, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-11-26
Recruiting
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
NCT07233239Focal Seizures
DrugCannabidiol
Jazz Pharmaceuticals
Phase 1
100
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Michigan
2025-11-26
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174Small Cell Lung Cancer
DrugsABBV-706·Lurbinectedin·Etoposide·Atezolizumab
AbbVie
Phase 2
180
Connecticut, Florida, Indiana, Kentucky, Massachusetts, Michigan, Missouri, Ohio
2025-11-25
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Arizona, California, Florida, Maryland, Michigan, Minnesota, Ohio, Rhode Island
2025-11-24
Active, closed
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015Atopic Dermatitis
DrugKT-621
Kymera Therapeutics, Inc.
Phase 2
200
Alabama, Arkansas, California, Florida, Illinois, Indiana, Michigan, New York
2025-11-24
Recruiting
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
NCT06971939Macular Telangiectasia Type 2 (MacTel)
Neurotech Pharmaceuticals
Phase 4
234
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-21
Recruiting
The RADIANCE CED Study
NCT07231757Hypertension, Cardiovascular Diseases, Vascular Diseases
ReCor Medical, Inc.
Observational
1,000
Michigan
2025-11-21
Recruiting
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
NCT07241039Advanced Squamous Tumors
DrugBudigalimab
AbbVie
Phase 1
220
California, Illinois, Michigan, North Carolina, Texas
2025-11-20
Recruiting
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Recruiting
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
NCT07205718Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2
223
California, Connecticut, Florida, Maryland, Michigan, Missouri, Ohio, Oregon
2025-11-19
By invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
DrugPembrolizumab
Rondo Therapeutics
Phase 1
149
California, Connecticut, Michigan, New York, North Carolina, South Carolina, Tennessee, Texas
2025-11-17
Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT07290803Atopic Dermatitis
Sanofi
Observational
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan
2025-11-17
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
DrugBimekizumab
UCB Biopharma SRL
Phase 3
320
Alabama, California, Florida, Michigan, Ohio, Oklahoma
2025-11-14
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
EvolveImmune United, Inc
Phase 1
160
California, Connecticut, Georgia, Michigan, New York, North Carolina, Ohio, Pennsylvania
2025-11-13
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845Ovarian Cancer
DrugsMirvetuximab Soravtansine·Bevacizumab·Carboplatin
AbbVie
Phase 2
400
California, Florida, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Montana
2025-11-13
Active, closed
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,060
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-11-12
Recruiting
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
NCT07281079Phelan-McDermid Syndrome
DrugNNZ-2591
Neuren Pharmaceuticals Limited
Phase 3
160
Alabama, California, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-12
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin
Boehringer Ingelheim
Phase 3
670
Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Maryland, Michigan
2025-11-07
Recruiting
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
NCT04008121Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
MediBeacon
Phase EARLY_PHASE1
10
Michigan
2025-11-06
Recruiting
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization
DrugAZD0292
AstraZeneca
Phase 2
435
California, Colorado, District of Columbia, Florida, Georgia, Kansas, Michigan, Minnesota
2025-11-06
Recruiting
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
NCT07223840Smoking
DrugBrenipatide
Eli Lilly and Company
Phase 2
222
Arkansas, Florida, Georgia, Michigan, Missouri, Nevada, New York, South Carolina
2025-11-03
Active, closed
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT07287644Hidradenitis Suppurativa (HS)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2/3
210
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Michigan
2025-11-03
Recruiting
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283Nonsegmental Vitiligo
DrugZasocitinib
Takeda
Phase 2
200
Arkansas, California, Florida, Louisiana, Maryland, Michigan, New York, Ohio
2025-11-03
Active, closed
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07214961Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC)
ARTBIO Inc.
Phase 1
80
Michigan, Nebraska, New Jersey
2025-11-03
Recruiting
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
NCT07098858Heart Failure
EBR Systems, Inc.
Observational
320
Arizona, Arkansas, Florida, Michigan, Missouri, New York, Ohio, Pennsylvania
2025-11-03
Recruiting
CCM OPEN HF Registry
NCT07112924Heart Failure
Impulse Dynamics
Observational
5,500
Arizona, Florida, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New Hampshire
2025-11-01
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2025-10-31
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
NCT07219615Chronic Spontaneous Urticaria
DrugsLitfulo·Ritlecitinib
Pfizer
Phase 2
200
Arizona, Arkansas, California, Colorado, Illinois, Maryland, Michigan, Oklahoma
2025-10-30
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Florida, Louisiana, Maryland, Michigan, Missouri, New Jersey, New York, Pennsylvania
2025-10-27
Recruiting
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT06405087Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-10-27
Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT07211178Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer
Tempus AI
Observational
900
Alabama, California, Florida, Illinois, Indiana, Michigan, Missouri, Nevada
2025-10-27
Active, closed
HEAL-4: Real-World Effectiveness of 4 Amniotic Allografts Adjunctive to Standard Care in DFU, VLU, and PU
NCT07223515Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Dynamic Medical Services dba Acesso Biologics
Observational
2,000
Michigan, Tennessee
2025-10-24
Recruiting
BoxX-NoAF Clinical Trial
NCT06989775Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative
AtriCure, Inc.
Not applicable
960
Arkansas, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-10-24
Recruiting
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
NCT07007962Immune Thrombocytopenia
DrugRilzabrutinib
Sanofi
Phase 3
60
California, Louisiana, Massachusetts, Michigan, Minnesota, New York, Oregon, Utah
2025-10-24
Recruiting
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
NCT06959121Atrial Fibrillation, Maze Procedure, AF, Ablation
Pulse Biosciences, Inc.
Not applicable
135
California, Florida, Michigan
2025-10-23
Recruiting
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
NCT07027514Non Small Cell Lung Cancer
DrugsTolododekin alfa·Cetrelimab
Ankyra Therapeutics, Inc
Phase 1
60
Florida, Illinois, Indiana, Michigan, Minnesota, New York, North Carolina, Pennsylvania
2025-10-22
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
140
California, Kentucky, Michigan, New Jersey, New York, Texas
2025-10-21
Recruiting
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System
NCT07227532Atrial Fibrillation
Biosense Webster, Inc.
Not applicable
276
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Michigan
2025-10-21
Active, closed
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
NCT07074977Chronic Pruritus of Unknown Origin
DrugNemolizumab
Galderma R&D
Phase 2
50
Alabama, Arizona, California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-10-20
Recruiting
Virtue® SAB in the Treatment of Coronary ISR Trial
NCT07045194Coronary Artery Disease
Orchestra BioMed, Inc
Not applicable
740
Florida, Indiana, Kansas, Maryland, Michigan, New York, North Carolina, Ohio
2025-10-20
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT07213609Neoplasms, Colorectal, Neoplasms
GlaxoSmithKline
Phase 1/2
47
Colorado, Michigan, Ohio, Tennessee
2025-10-20
Recruiting
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07006727Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
Novartis Pharmaceuticals
Phase 1
116
Iowa, Massachusetts, Michigan, Washington
2025-10-16
Recruiting
Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.
NCT07360418Diabetic Foot Ulcers (DFU), Foot Ulcer Chronic, Ulcer, Diabetic Foot Ulcer
Applied Biologics, LLC
Observational
50
Michigan
2025-10-16
Recruiting
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NCT06800963NMIBC
ImmunityBio, Inc.
Phase 1/2
40
Arizona, California, Georgia, Michigan, New York, Pennsylvania, Tennessee, Virginia
2025-10-15
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
DrugBexobrutideg
Nurix Therapeutics, Inc.
Phase 2
100
Arizona, California, Colorado, Florida, Indiana, Iowa, Maryland, Michigan
2025-10-15
Recruiting
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
NCT07115004Von Willebrand Disease (VWD)
DrugVGA039
Vega Therapeutics, Inc
Phase 3
60
Arkansas, California, Connecticut, Georgia, Michigan, Minnesota, North Carolina, Pennsylvania
2025-10-15
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
DrugsDurvalumab·Carboplatin
IDEAYA Biosciences
Phase 1/2
262
Colorado, Florida, Indiana, Michigan, New York, Pennsylvania, Tennessee, Texas
2025-10-14
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
DrugsTulisokibart·Methotrexate
Merck Sharp & Dohme LLC
Phase 2
185
Arizona, California, Colorado, Florida, Illinois, Michigan, Missouri, Nebraska
2025-10-08
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb
Observational
223
California, Florida, Georgia, Illinois, Maryland, Michigan, Montana, New Jersey
2025-10-08
Recruiting
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
NCT07023614Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.
Phase 2
165
California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2025-10-06
Recruiting
Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
NCT03836482Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
SeaStar Medical
Not applicable
20
Michigan
2025-10-02
Recruiting
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
NCT07175038Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
AllRock Bio, Inc.
Phase 2
40
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Michigan, Ohio
2025-10-01
Recruiting
Study of COYA 302 for the Treatment of ALS
NCT07161999Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics
Phase 2/3
120
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-10-01
Recruiting
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
NCT07181161Metastatic Prostate Cancer
DrugPalacaparib
AstraZeneca
Phase 1/2
283
Arkansas, California, Maryland, Massachusetts, Michigan, New York, Rhode Island, South Carolina
2025-10-01
Recruiting
IVUS CHIP UPP Registry
NCT06625801Coronary Artery Disease, Coronary Artery Disease Risk High, Complex Coronary Artery Disease
ECRI bv
Observational
1,010
Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan, Minnesota
2025-09-30
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, Pennsylvania
2025-09-30
Recruiting
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
NCT07192614Prostate Cancer
AstraZeneca
Phase 1/2
52
Florida, Massachusetts, Michigan, New York, Rhode Island
2025-09-30
Recruiting
TLN-372 in Advanced KRAS Mutant Solid Tumors
NCT07204340KRAS Mutant Solid Tumors
DrugsCetuximab·Pembrolizumab
Treeline Biosciences, Inc.
Phase 1
270
Alabama, Massachusetts, Michigan, Missouri, New York, Tennessee
2025-09-29
Recruiting
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
NCT07129993Urothelial Cancer, Bladder Cancer
DrugsDato-DXd·Gemcitabine·Cisplatin·Carboplatin
Daiichi Sankyo
Phase 2/3
630
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-09-26
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
DrugRilzabrutinib
Sanofi
Phase 3
124
California, Florida, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio
2025-09-26
Active, closed
Real-World Effectiveness of Amniotic Membrane Allografts Versus Standard Wound Care in DFU, VLU, and PU
NCT07223281Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Legacy Medical Consultants
Observational
2,400
Colorado, Michigan, Oklahoma, West Virginia
2025-09-25
Recruiting
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT07102381HER2-positive Breast Cancer, Breast Cancer
DrugsZanidatamab·Pertuzumab·Trastuzumab·Docetaxel
Jazz Pharmaceuticals
Phase 2
125
California, Colorado, Florida, Iowa, Louisiana, Maine, Maryland, Michigan
2025-09-24
Recruiting
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
NCT07136779Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc
Phase 1/2
310
Michigan, Texas, Utah, Virginia
2025-09-23
Recruiting
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
NCT07141706Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1
253
California, Michigan, Pennsylvania, Texas, Virginia
2025-09-23
Recruiting
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827Advanced Solid Tumor
DrugsAdrucil·Pembrolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas
2025-09-22
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
DrugsBNT326·Pumitamig
BioNTech SE
Phase 1/2
880
California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, New York, Ohio
2025-09-22
Recruiting
GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections
NCT06827990Aortic Dissection
W.L.Gore & Associates
Not applicable
112
Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-09-22
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
DrugGilteritinib
Astellas Pharma Global Development, Inc.
Phase 1
40
California, Colorado, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas
2025-09-22
Recruiting
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
NCT07023835Amyotrophic Lateral Sclerosis (ALS)
Zydus Therapeutics Inc.
Phase 2
240
California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Nebraska, North Carolina
2025-09-17
Recruiting
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
NCT07207707Solid Tumor Malignancies
Kumquat Biosciences Inc.
Phase 1
78
California, Colorado, Florida, Michigan, Ohio, Texas, Utah, Virginia
2025-09-16
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
DrugsApitegromab·Nusinersen·Risdiplam
Scholar Rock, Inc.
Phase 2
52
Arizona, California, Colorado, Georgia, Iowa, Michigan, Pennsylvania, Texas
2025-09-15
Active, closed
A Study in Subjects With Neurogenic Orthostatic Hypotension
NCT07089043Neurogenic Orthostatic Hypotension
CuraSen Therapeutics, Inc.
Phase 2
12
Arizona, Michigan, New Jersey, New York, Tennessee
2025-09-12
Recruiting
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
NCT07020819Guillain-Barre Syndrome
Annexon, Inc.
Phase 3
30
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-09-12
Recruiting
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
NCT07013201Palmoplantar Pustulosis
DrugDelgocitinib
LEO Pharma
Phase 2
135
California, Georgia, Michigan, New York, Ohio, Oregon, Pennsylvania
2025-09-11
Recruiting
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT07029828Severe Alopecia Areata
DrugsRitlecitinib higher·Ritlecitinib lower
Pfizer
Phase 3
140
California, Florida, Indiana, Maryland, Michigan, Nebraska, New Mexico, New York
2025-09-10
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
DrugsNavlimetostat·Iza-bren
Bristol-Myers Squibb
Phase 2
182
Alaska, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon, Washington
2025-09-09
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
NCT06689839Aortic Stenosis Treated With TAVI, Aortic Diseases
EnCompass Technologies, Inc.
Not applicable
500
Florida, Indiana, Michigan, Missouri, New York, Ohio, Virginia
2025-09-09
Recruiting
Post-Approval Study of the Neuspera Sacral Neuromodulation System
NCT07144813Urinary Urgency Incontinence
Neuspera Medical, Inc.
Not applicable
116
California, Florida, Indiana, Kansas, Kentucky, Louisiana, Michigan, Minnesota
2025-09-03
Recruiting
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
MBrace Therapeutics
Phase 1/2
150
California, Michigan, New Jersey, Texas, Utah, Virginia
2025-09-03
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
NCT07023289Colorectal Cancer
DrugTelisotuzumab Adizutecan
AbbVie
Phase 2
140
Alabama, California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2025-09-02
By invitation
Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
NCT07050160Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Lexeo Therapeutics
Observational
10
Michigan
2025-08-29
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Colorado, Florida, Maryland, Michigan, Missouri
2025-08-28
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
45
Florida, Iowa, Louisiana, Michigan, New York, Ohio, South Dakota, Texas
2025-08-28
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
Tasca Therapeutics
Phase 1/2
150
Colorado, Florida, Michigan, Missouri, Nebraska, North Carolina, Ohio, Pennsylvania
2025-08-27
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC
Phase 1
60
Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Tennessee, Texas
2025-08-27
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321Invasive Mold Infections
DrugFosmanogepix
Basilea Pharmaceutica
Phase 3
234
Alabama, California, Florida, Illinois, Kentucky, Maryland, Michigan, Minnesota
2025-08-26
Recruiting
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07020117Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
Aktis Oncology, Inc.
Phase 1
150
California, Florida, Iowa, Kansas, Maryland, Michigan, New York, Pennsylvania
2025-08-22
Recruiting
Advancement of Vestibular Intervention Via Portable Electrical Stimulator (VIPES)
NCT07466589Mild Traumatic Brain Injury, Concussion
Vivonics, Inc.
Not applicable
32
Michigan
2025-08-22
Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
NCT06959524Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Boston Scientific Corporation
Not applicable
1,616
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-08-21
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
DrugAZD0120
Alexion Pharmaceuticals, Inc.
Phase 1/2
91
Arizona, California, Florida, Massachusetts, Michigan, Minnesota, Missouri, New York
2025-08-18
Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
NCT07086976Autoimmune Haemolytic Anaemia
DrugRilzabrutinib
Sanofi
Phase 3
90
Arizona, California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, Minnesota
2025-08-18
Recruiting
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
NCT06868485Non Small Cell Lung Cancer
DrugWSD0922-FU
Wayshine Biopharm, Inc.
Phase 2
40
California, Florida, Michigan, New Jersey, Ohio, Pennsylvania, Texas, Virginia
2025-08-18
Recruiting
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT07085091NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
ALX Oncology Inc.
Phase 1
170
California, Florida, Michigan, New Jersey, Ohio, Oregon, Texas, Utah
2025-08-18
Recruiting
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07123103Solid Tumors
Exelixis
Phase 1
150
Arkansas, California, District of Columbia, Florida, Michigan, New Jersey, North Carolina, Texas
2025-08-18
Recruiting
Thermoacoustic Method for Estimating Liver Fat Fraction
NCT07321925MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
Endra Lifesciences
Observational
49
Michigan
2025-08-15
Recruiting
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT07096674Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
90
Alabama, California, Florida, Georgia, Michigan, Nevada, North Carolina, Ohio
2025-08-12
Recruiting
Janus II Feasibility
NCT06556693Sleep Apnea
Zoll Medical Corporation
Not applicable
40
Arizona, Michigan, Ohio
2025-08-12
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
DrugsBNT326·Paroxetine·Itraconazole·Pumitamig
BioNTech SE
Phase 1/2
1,438
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New York
2025-08-12
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
California, Florida, Indiana, Kentucky, Maryland, Michigan
2025-08-11
Recruiting
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849Sickle Cell Disease Vaso-occlusive Crisis
DrugIVIG
CSL Behring
Phase 2
70
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, Missouri
2025-08-07
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
DrugBaxdrostat
AstraZeneca
Phase 3
250
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Mississippi
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
California, Florida, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania
2025-08-06
Recruiting
OM336 in Autoimmune Cytopenias
NCT07083960AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
Lakefront Biotherapeutics West LLC
Phase 1
32
California, District of Columbia, Michigan, Washington
2025-08-01
Recruiting
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
NCT06298916Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
Lantheus Medical Imaging
Phase 1/2
26
California, Michigan, Ohio
2025-08
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
DrugsRitlecitinib higher·Ritlecitinib lower
Pfizer
Phase 3
208
California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland, Michigan
2025-07-31
Recruiting
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
NCT07024693Fuchs Endothelial Corneal Dystrophy, Fuchs
Design Therapeutics, Inc.
Phase 2
70
Indiana, Michigan
2025-07-30
Active, closed
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
DrugBL-M05D1
SystImmune Inc.
Phase 1
160
Arizona, California, Colorado, Connecticut, Louisiana, Michigan, New Jersey, Tennessee
2025-07-30
Recruiting
Study of BHV-1400 in IgA Nephropathy
NCT07054684IgA Nephropathy
Biohaven Therapeutics Ltd.
Phase 1
20
Connecticut, Florida, Georgia, Illinois, Indiana, Michigan, Missouri, South Dakota
2025-07-30
Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
120
Michigan, Missouri, Pennsylvania, Texas, Virginia
2025-07-29
Recruiting
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
NCT07080905Hemophilia B
CSL Behring
Phase 3
20
California, Florida, Georgia, Michigan, Tennessee
2025-07-28
Not yet open
A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis
NCT06989567Sickle Cell Disease
DrugL-Citrulline
Asklepion Pharmaceuticals, LLC
Phase 3
120
District of Columbia, Florida, Georgia, Maryland, Michigan, North Carolina
2025-07-25
Recruiting
ELEVATE High-Risk PCI Pivotal Study
NCT07001332High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Magenta Medical Ltd.
Not applicable
290
Arizona, California, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-07-25
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
DrugPanitumumab
Astellas Pharma Inc
Phase 1
364
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Active, closed
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503Asthma (Diagnosis)
DrugWIN378
Windward Bio
Phase 2
136
California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska
2025-07-24
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634Breast Cancer
DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole
Celcuity Inc
Phase 3
1,180
California, Florida, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Missouri
2025-07-24
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960Multiple Myeloma
DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone
AbbVie
Phase 1/2
325
California, Connecticut, Massachusetts, Michigan, New York, North Carolina, Oregon, Texas
2025-07-23
Active, closed
Combination Gerotherapeutic Interventions for Healthspan Improvement
NCT07475546Healthspan Improvement, Aging, Longevity
DrugsGlutathione·Naltrexone·Rapamycin·Sirolimus
AgelessRx
Phase 3
30
Michigan
2025-07-23
Recruiting
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
NCT07356453Advanced Solid Tumors
FoRx Therapeutics AG
Phase 1
40
California, Michigan, Missouri, Oregon, Texas, Virginia
2025-07-22
Recruiting
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
NCT06888921Ovarian Cancer, Ovarian Cancer Recurrent
Compugen Ltd
Phase 1/2
60
Georgia, Illinois, Massachusetts, Michigan, New York, North Carolina, Ohio, Oklahoma
2025-07-21
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan, Mississippi
2025-07-21
Recruiting
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
NCT06779630Coronary Artery Disease
Teleflex
Not applicable
150
California, Kansas, Massachusetts, Michigan, Missouri, New York, Texas, West Virginia
2025-07-18
Active, closed
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07090330Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
80
California, Connecticut, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan
2025-07-18
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
NCT07079631Metastatic Colorectal Cancer
DrugsBNT314·Pumitamig·Bevacizumab
BioNTech SE
Phase 1/2
482
Connecticut, Michigan, Ohio, Texas
2025-07-18
Recruiting
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
NCT07069712Gastroesophageal Adenocarcinoma
DrugsSonesitatug Vedotin·Calcium folinate·Rilvegostomig·Trastuzumab deruxtecan
AstraZeneca
Phase 2
100
Delaware, District of Columbia, Kansas, Michigan, New York, Pennsylvania
2025-07-17
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri
2025-07-17
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2025-07-16
Recruiting
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
NCT07017933Renal Impairment After Cardiac Surgery, Renal Impairment, Acute Kidney Injury
3ive Labs
Not applicable
124
Florida, Michigan, North Carolina, Ohio
2025-07-16
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
DrugIrinotecan
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Active, closed
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
NCT07105488Atopic Dermatitis (AD)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2
225
Arizona, California, Florida, Georgia, Indiana, Louisiana, Massachusetts, Michigan
2025-07-15
Recruiting
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
NCT06891755COPD, Emphysema
Apreo Health, Inc.
Not applicable
250
Alabama, Arizona, California, Florida, Illinois, Kansas, Massachusetts, Michigan
2025-07-15
Recruiting
Shield Post-Approval Study Protocol
NCT06880055Colo-rectal Cancer
Guardant Health, Inc.
Observational
3,375
Arizona, California, Connecticut, Florida, Illinois, Kansas, Louisiana, Michigan
2025-07-14
Recruiting
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
NCT06898515Acute Decompensated Heart Failure
DrugFurosemide
Reprieve Cardiovascular, Inc
Phase 3
400
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Minnesota
2025-07-14
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732Alzheimer Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Florida, Louisiana, Maryland, Massachusetts, Michigan
2025-07-10
Recruiting
Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
NCT06964685AMI Cardiogenic Shock
Abiomed Inc.
Observational
350
Arkansas, California, Florida, Hawaii, Illinois, Massachusetts, Michigan, New Mexico
2025-07-10
Recruiting
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
NCT07048808Refractory Angina, Coronary Artery Disease
XyloCor Therapeutics, Inc.
Phase 2
106
Alabama, Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, North Carolina
2025-07-08
Active, closed
A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
NCT06975722Ulcerative Colitis
DrugBrivekimig
Sanofi
Phase 2
99
California, Florida, Georgia, Iowa, Massachusetts, Michigan, Missouri, New York
2025-07-07
Active, closed
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556Metastatic Hormone-sensitive Prostate Cancer
DrugsLuxdegalutamide·Abiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 2
168
California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-07-07
Recruiting
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272Castration-Resistant Prostatic Cancer, Metastasis
DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide
Merck Sharp & Dohme LLC
Phase 1/2
360
California, District of Columbia, Michigan, New York, Pennsylvania, Tennessee, Washington
2025-07-03
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762Advanced Solid Tumor
DrugBevacizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Arizona, California, Connecticut, Kansas, Michigan, New York, North Carolina, Ohio
2025-07-02
Not yet open
GyroGlove Use in Essential Tremor Patients
NCT05958030Essential Tremor
GyroGear Ltd
Not applicable
30
Michigan, Texas, Vermont
2025-07
Recruiting
A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
NCT06937931Cervical Dystonia
DrugCorabotase
Ipsen
Phase 2
132
Arizona, California, Florida, Georgia, Illinois, Michigan, New York, Washington
2025-06-30
Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Alabama, Arizona, California, Colorado, Florida, Kentucky, Michigan, Minnesota
2025-06-27
Recruiting
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
NCT06665100Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
Pulmotect, Inc.
Phase 2
100
California, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York
2025-06-27
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
DrugsVS-7375·Erbitux·Cetuximab·Nab-paclitaxel
Verastem, Inc.
Phase 1/2
295
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
NCT07082803Lymphoma, Lymphoma, Non Hodgkin
DrugZeprumetostat
Treeline Biosciences, Inc.
Phase 1
180
California, Michigan, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-06-23
Recruiting
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
NCT06972446Rheumatoid Arthritis
DrugsABBV-8736·ABBV-701·Lutikizumab·Adalimumab
AbbVie
Phase 2
180
Arizona, Arkansas, California, Colorado, Florida, Illinois, Louisiana, Michigan
2025-06-20
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
981
California, Delaware, Florida, Georgia, Illinois, Maryland, Michigan, Missouri
2025-06-20
Recruiting
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
NCT06850623Locally Advanced Pancreatic Adenocarcinoma
DrugModified FOLFIRINOX
EXACT Therapeutics AS
Phase 2
25
Arizona, California, Massachusetts, Michigan, Pennsylvania, Rhode Island
2025-06-19
Recruiting
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
NCT06608823Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
JenaValve Technology, Inc.
Not applicable
1,016
California, District of Columbia, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-06-18
Recruiting
AERA Pediatrics Registry
NCT07071298Dysfunction of Eustachian Tube
Integra LifeSciences Corporation
Observational
300
California, Massachusetts, Michigan, Minnesota, Ohio, Pennsylvania, Texas, Utah
2025-06-17
Active, closed
An Observational Study of Individuals With Isolated Dystonia
NCT07111663Isolated/Primary Dystonia That Affects More Than One Region of the Body
Vima Therapeutics
Observational
200
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan
2025-06-17
Recruiting
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
NCT07030907Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
Outpace Bio, Inc.
Phase 1
30
Michigan, Minnesota, New York, Texas
2025-06-16
Recruiting
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT07051629Epilepsy, Healthy Volunteer
Suninflam Inc
Phase 1
88
Arizona, Florida, Hawaii, Maryland, Michigan, New York, North Carolina, Texas
2025-06-16
Recruiting
A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.
NCT06283979Pressure Ulcer, Stage IV, Osteomyelitis
Biocomposites Ltd
Phase 2
60
Arizona, Illinois, Michigan, Mississippi, Missouri, Nebraska, New Jersey, New York
2025-06-15
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
NCT07024823Chronic Kidney Disease
AstraZeneca
Phase 1
124
California, Illinois, Michigan, Minnesota, Texas
2025-06-09
Recruiting
Contactless Optical Monitoring of AV Access Using the PatenSee System in Outpatient Hemodialysis Patients
NCT07194395Hemodialysis, Clinical Assessment
PatenSee Ltd.
Observational
90
Michigan
2025-06-06
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490Multiple Sclerosis Spasticity
DrugIrafamdastat
Celgene
Phase 2
200
Alabama, Arizona, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri
2025-06-05
Recruiting
Study of AUBE00 in Patients With Solid Tumors
NCT07030959Solid Tumors
DrugCetuximab
Chugai Pharmaceutical
Phase 1
130
Michigan, Texas, Virginia
2025-06-05
By invitation
Virtuos Bone Graft in Lumbar Fusion
NCT06686017Degenerative Disc Disease
Orthofix Inc.
Observational
150
Indiana, Michigan, Montana, North Carolina, South Carolina, Texas, Virginia
2025-06-05
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536Crohn's Disease
DrugBrivekimig
Sanofi
Phase 2
99
Arizona, California, Florida, Georgia, Iowa, Kansas, Massachusetts, Michigan
2025-06-03
Active, closed
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667Obesity
DrugCagriSema
Novo Nordisk A/S
Phase 3
609
California, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri
2025-06-03
Active, closed
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
NCT06852963Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease, Eye Diseases Hereditary
PYC Therapeutics
Phase 1/2
17
Florida, Michigan, Oregon, Texas
2025-06-01
Recruiting
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
NCT06969430Acute Myeloid Leukemia
Debiopharm International SA
Phase 1/2
154
California, Florida, Illinois, Michigan, New York, Ohio, Texas
2025-05-30
Active, closed
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093Obesity, Overweight, Chronic Low Back Pain (CLBP)
DrugRetatrutide
Eli Lilly and Company
Phase 3
586
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-05-29
Recruiting
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT06533644Metastatic Castration-resistant Prostate Cancer
Syncromune, Inc.
Phase 2
91
Arizona, Arkansas, California, Florida, Illinois, Kansas, Louisiana, Michigan
2025-05-29
Active, closed
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
NCT07023731KRAS G12D Mutation, Advanced Solid Cancer
Arvinas Inc.
Phase 1/2
76
Arizona, Connecticut, Florida, Indiana, Michigan, New York, North Carolina, Ohio
2025-05-29
Active, closed
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
NCT06917404Osteoarthritis, Knee
DrugPentosan Polysulfate Sodium
Paradigm Biopharmaceuticals Ltd.
Phase 3
466
Arizona, California, Florida, Illinois, Maryland, Michigan, Nebraska, Nevada
2025-05-29
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
DrugsMIRV·Mirvetuximab Soravtansine
AbbVie
Phase 2
110
Florida, Kentucky, Massachusetts, Michigan, Pennsylvania, Texas
2025-05-28
Recruiting
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
NCT06787612Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsREGN10597·Ubamatamab·Sarilumab·Fianlimab
Regeneron Pharmaceuticals
Phase 2
297
Alabama, California, Florida, Illinois, Kansas, Kentucky, Massachusetts, Michigan
2025-05-28
Recruiting
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
NCT06941272Malignant Neoplasm
DrugPatritumab deruxtecan
Merck Sharp & Dohme LLC
Phase 1/2
50
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-05-26
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
DrugsFelzartamab·Tacrolimus
Biogen
Phase 3
180
Alabama, California, Michigan, New York, North Carolina, Ohio, Tennessee, Texas
2025-05-22
Recruiting
Minima Stent System Post- Approval Study (PAS)
NCT06828770Pulmonary Artery Stenosis, Aortic Coarctation
Renata Medical
Observational
100
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-05-21
Active, closed
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479Severe Asthma
DrugVerekitug
Upstream Bio Inc.
Phase 2
396
California, Florida, Idaho, Maryland, Michigan, Nevada, New York, Ohio
2025-05-21
Recruiting
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
NCT06834165Allergic Reactions
DrugAdrenaline
ARS Pharmaceuticals, Inc.
Phase 4
600
California, District of Columbia, Illinois, Michigan, New York, Ohio
2025-05-20
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581Asthma
DrugTilrekimig
Pfizer
Phase 2
252
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kansas, Michigan
2025-05-20
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-19
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
NCT06990867Acute Ischemic Stroke
Corxel Pharmaceuticals
Phase 2/3
740
California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maryland, Michigan
2025-05-15
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Recruiting
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
350
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, New York
2025-05-14
Recruiting
A Study of ZL-1310 in Participants With Selected Solid Tumors
NCT06885281Solid Tumors
DrugZL-1310
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
California, Illinois, Michigan, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-05-12
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Arkansas, California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Missouri
2025-05-08
Recruiting
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
NCT06952699Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2
88
Alabama, Arizona, California, Colorado, Florida, Georgia, Maryland, Michigan
2025-05-06
Recruiting
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
NCT06680037B-cell Mediated Autoimmune Disorders
DrugAzer-cel
TG Therapeutics, Inc.
Phase 1
100
California, Michigan, Nebraska, New York, Ohio, Wisconsin
2025-05-06
Recruiting
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
NCT06975293Solid Tumor, Sarcoma, Leiomyosarcoma, Dedifferentiated Liposarcoma
STORM Therapeutics LTD
Phase 1/2
107
California, Massachusetts, Michigan, New York, Texas, Virginia
2025-05-05
Recruiting
Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962Crohns Disease
DrugsTRX103·Cyclophosphamide
Tr1X, Inc.
Phase 1/2
39
Arizona, California, Florida, Illinois, Iowa, Kentucky, Michigan, Minnesota
2025-05-05
Recruiting
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT06730347Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary
MacroGenics
Phase 2
80
California, Louisiana, Michigan, Pennsylvania, Texas, Wisconsin
2025-05-01
Active, closed
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
NCT06924970Sickle Cell Disease
DrugTebapivat
Agios Pharmaceuticals, Inc.
Phase 2
59
Connecticut, District of Columbia, Georgia, Michigan, New York, Pennsylvania, South Carolina, Texas
2025-05-01
Recruiting
SPYRAL GEMINI Pilot Study
NCT06907147Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
175
California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Nevada, New Jersey
2025-05-01
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Recruiting
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
NCT06626919Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases
DrugsAnitocabtagene Autoleucel·Fludarabine·Cyclophosphamide
Arcellx, Inc.
Phase 1
30
California, Florida, Michigan, Minnesota, New York, Ohio, Oregon, Pennsylvania
2025-04-30
Recruiting
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
NCT06937177Cancer Weight Loss
Endevica Bio
Phase 2
120
Arizona, California, Florida, Georgia, Illinois, Kansas, Michigan, Nebraska
2025-04-28
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
Tyra Biosciences, Inc
Phase 1
125
California, Kansas, Maryland, Massachusetts, Michigan, New York, Tennessee
2025-04-24
Recruiting
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770Severe Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
288
California, Connecticut, Illinois, Indiana, Kansas, Michigan, Missouri, Nebraska
2025-04-24
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463Metastatic Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Panitumumab·Fluorouracil·Leucovorin
AbbVie
Phase 2
390
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2025-04-24
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
DrugPumitamig
BioNTech SE
Phase 1/2
380
California, Florida, Georgia, Illinois, Michigan, Missouri, New Jersey, New York
2025-04-23
Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
Tanabe Pharma America, Inc.
Phase 1/2
27
California, Michigan, Ohio, Texas
2025-04-18
Active, closed
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
NCT06907511Pandemic Influenza Immunization, Healthy Volunteers
Sanofi
Phase 1/2
720
California, Florida, Georgia, Michigan, Nebraska, Ohio, South Carolina, Texas
2025-04-17
Recruiting
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
NCT06909214New Onset Generalized Myasthenia Gravis (gMG)
DrugEfgartigimod PH20
argenx
Phase 4
30
California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Michigan, Ohio
2025-04-17
Recruiting
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248Multiple Sclerosis
DrugMRNA-1195
ModernaTX, Inc.
Phase 2
180
Massachusetts, Michigan, Missouri, Oklahoma, Texas
2025-04-16
Recruiting
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06673017Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
PanTher Therapeutics
Phase 1
26
California, Florida, Michigan, New York, Texas, Washington
2025-04-14
By invitation
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
NCT06848088Melanoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
48
California, Colorado, Kansas, Michigan, New Jersey, Tennessee, Texas, Virginia
2025-04-14
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax
BeOne Medicines
Phase 3
250
Arkansas, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2025-04-10
Recruiting
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
NCT05066217Lennox Gastaut Syndrome
DrugClemizole HCl
Epygenix
Phase 3
260
Arkansas, California, Florida, Illinois, Kentucky, Michigan, Minnesota, Nebraska
2025-04-09
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-04-09
Active, closed
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
710
California, Florida, Georgia, Illinois, Indiana, Kansas, Maryland, Michigan
2025-04-09
Recruiting
Tissue Reinforcement for Breast Reconstruction (TRBR) Pivotal Clinical Study (REDEFINE)
NCT06556654Breast Reconstruction Surgery
W.L.Gore & Associates
Not applicable
180
Arizona, California, Florida, Illinois, Kansas, Maryland, Michigan, Mississippi
2025-04-09
Rows per page Showing 1–500 of 1484
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/michigan

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,484 of those studies with a site in Michigan.

How many clinical trials are recruiting in Michigan?

834 of the 1,484 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 24 have not yet opened recruitment, 598 are active but closed to new participants, and 28 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Michigan), 1,484 studies
PhaseStudiesRecruitingShare
Phase 333515522.6%
Phase 229617019.9%
Phase 125016116.8%
Phase 1/222414915.1%
Not applicable1678211.3%
Observational140729.4%
Phase 2/341272.8%
Phase 427161.8%
Phase EARLY_PHASE1420.3%

Most active sponsors

Lead sponsors with the most studies (Michigan)
Lead sponsorStudiesRecruiting
AstraZeneca5324
Janssen Research & Development, LLC4118
Eli Lilly and Company4022
AbbVie3518
Merck Sharp & Dohme LLC3420
Hoffmann-La Roche309
Novartis Pharmaceuticals2916
Pfizer2614
Regeneron Pharmaceuticals2416
Bristol-Myers Squibb2212
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.